



Orexigen Therapeutics, Inc.
3344 North Torrey Pines Court
Suite 200
La Jolla, CA 92037
Phone: 858-875-8600
Fax: 858-875-8650
www.orexigen.com

March 12, 2018

Dear Orexigen Therapeutics, Inc. Supplier:

As one of our valued suppliers, I want to share with you that Orexigen Therapeutics, Inc. (“Orexigen” or “the Company”) has announced the decision to sell all of the assets of the company by the end of June using a structured process through Chapter 11 of the U.S. Bankruptcy Code. The Company’s normal day-to-day operations will continue without interruption. Orexigen remains completely focused on maintaining strong relationships with its suppliers and serving its customers.

Our goal is to minimize disruption as much as possible for our business partners and our customers. We know how important it is to have product available to you, your customers and to patients. Orexigen has put forward specific motions with the Bankruptcy Court to continue key aspects of our distribution channel, including the supply of product.

In addition, Orexigen filed a variety of customary first day motions with the Bankruptcy Court in Delaware, which will help enable it to continue to conduct business as usual while it completes the sale of its assets. These First Day Motions (the “Motions”) seek court orders to approve, among other things, authorization for the Company to continue to:

- Use its current cash and cash generated from operations in the ordinary course of business
- Use the Company’s current cash management systems and maintain all existing bank accounts
- Fund all employee wages, benefits and related payments in the ordinary course of business without interruption
- Provide uninterrupted services to all of its customers
- Honor customer obligations and deposits
- Pay shippers and those currently processing and refining the Company’s goods
- Fund utility payments in the ordinary course

The First Day Motions and related bankruptcy filings can be seen on the public website at www.kccllc.net/orexigen.

Additionally, the Company has received a \$35M loan commitment, which is subject to court approval, that enables the company to continue to operate our business through the planned sale period. These funds will satisfy customary obligations associated with ongoing operations of the Company’s business, including payment of post-petition obligations to vendors under existing terms.

Orexigen was founded on the premise of helping to improve the health and lives of patients struggling to lose weight, and we remain as committed as ever to that mission. Contrave® (naltrexone HCl and bupropion HCl extended release) is the #1 prescribed weight loss brand and almost 800,000 patients have benefitted from CONTRAVE since launch¹, but we also know that many more patients could benefit. Through this near-term sale, along with our continued, active promotion, and support from providers such as yourself, we confidently intend to serve the growing patient demand.

CONTRAVE is a prescription weight-loss medicine that may help some adults with a body mass index (BMI) of 30 kg/m² or greater (obese), or adults with a BMI of 27 kg/m² or greater (overweight) with at least one weight-related medical problem such as high blood pressure, high cholesterol, or type 2 diabetes, lose weight and keep the weight off.

One of the ingredients in CONTRAVE, bupropion, may increase the risk of suicidal thinking in children, adolescents, and young adults. CONTRAVE patients should be monitored for suicidal thoughts and behaviors. In patients taking bupropion for smoking cessation, serious neuropsychiatric adverse events have been reported. CONTRAVE is not approved for use in children under the age of 18.

Thank you in advance for your ongoing support. We look forward to a long and prosperous business relationship.

Very truly yours,

A handwritten signature in black ink, appearing to read "Michael Narachi". The signature is fluid and cursive, with the first name "Michael" and last name "Narachi" clearly distinguishable.

Michael Narachi
President & Chief Executive Officer